Scientists are diversifying their approaches to finding an effective treatment for Alzheimer’s as clinical trials targeting beta-amyloid plaques, one of the hallmarks of the…
In 2013, Amylyx Pharmaceuticals co-founders Justin Klee and Josh Cohen, undergraduate students at Brown University at the time, hypothesized that targeting two dysfunctional pathways…
Developing a new drug start to finish can take years — even decades — and cost billions. But, there’s a shortcut: repurposing old drugs…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the Charter…
Sponsored: This article was produced by Being Patient in partnership with Charter Research. More information on Alzheimer’s clinical trials can be found on the…
Some drug developers have put stock in the cholinergic hypothesis, developing a type of medication known as cholinesterase inhibitors. While Alzheimer’s still has no…
Researchers at the Salk Institute for Biological Studies have reported that a drug candidate called CMS121 has successfully halted and possibly reversed memory loss in…
Alzheimer’s Disease takes hundreds of thousands of lives every year, affecting 47 million people worldwide. But so far, no amount of urgency, nor billions…
About seven out of ten cases of Alzheimer’s are accompanied by symptoms of agitation and aggression. This could mean pacing, restlessness, shouting and screaming,…
Targeting beta-amyloid protein before symptoms of cognitive decline or Alzheimer’s appear is the goal of one trial out of the National Institute on Aging…